About 80% of breast cancer occurs in women with no family history. Estrogen affects the function of several target tissues and research has shown that increased lifetime exposure to estrogen is a major risk factor in the development of breast cancer. Estrogen Genetic Testing to detect genetic variants that have been shown to impact the way estrogen is metabolized. This test is useful to guide the personalization of recommendations for diets, hormones and nutritional supplements, based on the knowledge acquired with the Genetic Estrogen Test. Improving estrogen metabolism is beneficial for men and women who suffer from numerous estrogen-dominant conditions and who have increased lifetime exposure to estrogens, estrogen metabolites, and other carcinogens.
Clinical value:
Recommended for:
- Men or women with a strong family history of breast, ovarian, colon or prostate cancer.
- Women suffering from estrogen-dominant diseases such as endometriosis, premenstrual syndrome, and uterine fibroids.
- Women considering oral contraceptives, hormone replacement therapy, or bioidentical hormone supplements.
- Women who are considering in vitro fertilization or who have been diagnosed with estrogen receptor-positive breast cancer.
Estrogen DNA Test Report Provides:
- The level of impact of any genetic variants identified.
- An explanation of its impact on estrogen metabolism.
- Appropriate nutritional and lifestyle recommendations to support healthy estrogen metabolism.
Analytes measured:
CYP1A1: Phase I cytochrome P450 enzyme that converts environmental procarcinogens to reactive intermediates that have carcinogenic effects. In addition, it participates in the oxidative metabolism of estrogens.
CYP1B1: It catalyzes the 4-hydroxylation of estradiol and active polycyclic aromatic hydrocarbons (PAHs) and arylamines.
CYP17A: It catalyzes reactions involved in drug metabolism and the synthesis of cholesterol, steroids and other lipids as an integral part of the estrogen metabolism pathway.
MnSOD: Provides antioxidant activity within the cell, necessary to reduce oxidative damage caused by reactive estrogen metabolites.
GSTM1: Responsible for the elimination of xenobiotics, carcinogens and oxidative stress products, including reactive estrogen metabolites.
GSTT1: Member of a superfamily of proteins that catalyze the conjugation of reduced glutathione and is responsible for the elimination of reactive products of estrogen metabolism.
COMT: It influences the levels of certain hormones and participates in the methylation and inactivation of catecholestrogens.
MTHFR: MTHFR is a key enzyme in the folate metabolism pathway: it directs dietary folate to DNA synthesis or homocysteine remethylation. Decreased MTHFR enzyme activity has been associated with an increased risk of premenopausal breast cancer with long-term estrogen exposure.
SULT1A1: Involved in the inactivation of estrogens and bioactivation of heterocyclic amines and polycyclic aromatic hydrocarbons.
NQO1: Quinone reductase is primarily involved in the detoxification of potentially mutagenic and carcinogenic quinones derived from tobacco smoke, diet, and estrogen metabolism.
Factor V: The factor V Leiden gene mutation is characterized by a poor anticoagulant response to activated protein C and an increased risk of venous thromboembolism.
Privacy Policy:
The DNA and original sample material are destroyed after 3 months, so that no names or other identifiers remain on the samples. Samples are analyzed only for the SNPs included in DNALife tests, and no other investigations or analyzes are performed without separate permission from the patient. We do not give or sell the results to third parties.
